Ev Williams

Apr 16, 2021

1 min read

First off, Recursion was a loooong and often lonely journey for the founders. The idea was met with near-universal skepticism. The company’s entire approach to disease biology was antithetical to conventional thinking in life science. The complexity of the platform was off-putting to both tech and biotech investors for a multitude of reasons. Industry partners simultaneously dismissed the platform for not being relevant and gave feedback that phenotypic screening was played out. The team built Recursion up in the face of tremendous adversity and remained confident in the first principles of the approach and the data that the platform was generating.

To RXRX and Beyond
166
1

Nan Li

--

--

More from Ev Williams

CEO of Medium, partner at Obvious Ventures, co-founder of Twitter, aspiring motivational speaker 🤸‍♂️

Love podcasts or audiobooks? Learn on the go with our new app.

Try Knowable

AboutHelpTermsPrivacy

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Ev Williams

Ev Williams

CEO of Medium, partner at Obvious Ventures, co-founder of Twitter, aspiring motivational speaker 🤸‍♂️

More from Medium

BU Experts

AANHPI Heritage Month: Examining the role of media portrayals

TheSoul Publishing

TheSoul Publishing and Lockwood Publishing Launch ‘The Summer of Metaverse Music Events’

Laura Hertzfeld

The newsroom matchmaker

Colorful painted silos
Monika Stankova

in

Names With Stories

Names with stories: The story behind Mentessa.com

Help

Status

Writers

Blog

Careers

Privacy

Terms

About

Knowable